About Dr. Brian Caveney
Caveney, a nationally recognized health policy expert, joined LabCorp as chief medical officer in 2017. In this role, he has broad responsibility for the medical and scientific strategy of the enterprise. He also currently serves as the company’s head of managed care. Most recently, Caveney was chief medical officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC), where he joined in 2011. In addition to various roles in the Healthcare Division of the core health plan, Caveney also served as chief clinical officer of Mosaic Health Solutions, a wholly owned subsidiary of Blue Cross NC for strategic investments in diversified health solutions businesses. Prior to joining Blue Cross NC, Caveney was a practicing physician and assistant professor at Duke University Medical Center. Caveney holds an M.D. from the West Virginia University School of Medicine, a J.D. from the West Virginia University College of Law and an M.P.H. in health policy and administration from the University of North Carolina at Chapel Hill. He completed his residency at Duke University Medical Center and is board-certified in preventive medicine, with a specialty in occupational and environmental medicine.
About Mark Schroeder
Schroeder has more than a decade of experience with LabCorp, having joined in 2007. He assumed the role of enterprisewide chief supply chain officer in 2016. In that role, he is responsible for LabCorp’s global supply chain management function and overseeing Diagnostics and Drug Development supply chain operations around the world. These operations span a wide variety of sectors, including lab operations, logistics, sourcing and procurement, aviation, real estate, and the corporate program management office. His experience also has included operational leadership roles over genetics and oncology, and over one of the company’s core divisions. Schroeder is the executive sponsor for LaunchPad, the company’sre-engineering and process improvement initiatives spanning Diagnostics and Drug Development globally. He serves on the board of LabCorp’s venture fund and on the FedEx Healthcare Industry Advisory Board. Schroeder has a bachelor’s degree in interdisciplinary engineering and management from Clarkson University.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory andend-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11 billion in 2018. To learn more about LabCorp, visitwww.LabCorp.com, and to learn more about Covance Drug Development, visitwww.Covance.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to the Company’s leadership, future operations and opportunities. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the performance of employees and executives, the willingness of employees and executives to remain employed, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or
2
